Eupraxia Pharmaceuticals Increases R&D Spending Amid Clinical Trials
The clinical-stage biotechnology company reported a net loss of $27.1 million for the six months ended June 30, 2026
Eupraxia Pharmaceuticals Inc. (EPRX), a clinical-stage biotechnology company, reported a net loss of $27.1 million for the six months ended June 30, 2026. The company, which has not yet generated revenue from operations, saw its accumulated deficit grow to $196.7 million as of that date.
Research and development expenses rose significantly as the company progressed its pipeline. For the three months ended June 30, 2026, research and development costs were $12.8 million, compared to $5.2 million for the same period in 2025. For the first six months of 2026, these expenses totaled $23.9 million, up from $9.0 million in the first half of 2025.
These expenditures supported the development of the company's Diffusphere technology, specifically the EP-104GI product candidate for eosinophilic esophagitis (EoE). In April 2026, the company announced nine-month data from its Phase 1b/2a RESOLVE trial, noting that 66% of patients in the highest dose cohort maintained clinical remission in symptoms at week 36.
To fund these activities, the company raised approximately $58.6 million through a public offering of common shares and pre-funded warrants on February 20, 2026. As of June 30, 2026, Eupraxia held $52.4 million in cash and cash equivalents and $81.2 million in short-term investments.
Cash used in operating activities for the six months ended June 30, 2026, was $23.2 million, an increase from the $14.3 million used during the same period in 2025. The company said its continued operations are dependent on its ability to generate future cash flows or obtain additional funding through equity financing, grants, or strategic partnering.
Eupraxia expects to release interim data from its Phase 2b EoE trial in the fourth quarter of 2026, with plans to initiate a Phase 3 trial and expand the EP-104GI target indications to a broader gastrointestinal portfolio in 2027.